Cognition Therapeutics, Inc. ( (CGTX) ) has released its Q3 earnings. Here is a breakdown of the information Cognition Therapeutics, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system, with a unique approach targeting the sigma-2 receptor.
In its third quarter 2025 earnings report, Cognition Therapeutics highlighted significant progress in its clinical programs, including a $30 million direct offering to support the development of its lead candidate, zervimesine (CT1812), and alignment with the FDA on a registrational path for Alzheimer’s disease.
Key financial metrics revealed a net loss of $4.9 million for the quarter, a notable improvement from the $9.9 million loss in the same period of 2024. The company also reported reduced research and development expenses, attributed to the completion of certain clinical trials, and a decrease in general and administrative expenses due to lower stock-based compensation costs.
Strategically, Cognition Therapeutics is advancing its clinical studies, with over 75% enrollment in the Phase 2 ‘START’ study for early Alzheimer’s disease. The company is also conducting necessary pharmacology and bioavailability studies to prepare zervimesine for further development across multiple indications.
Looking ahead, Cognition Therapeutics remains optimistic about its financial position, with sufficient cash reserves to fund operations into the second quarter of 2027, as it continues to pursue its clinical and regulatory milestones for zervimesine and other pipeline candidates.